Serial #79387728
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

Serial #79387728 Trademark

Serial Number: 79387728 • Registration: 7854096

Serial #79387728 is a trademark filed by XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. on November 2, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. (3 trademarks)

Unit 201, Building 3, Zone B

Entity Type: 98

XellSmart Biomedical(Suzhou) Co. Ltd.

Unit 201, Building 3, Zone B,

Entity Type: 99

Trademark Details

Filing Date

November 2, 2023

Registration Date

July 8, 2025

Published for Opposition

May 20, 2025

Goods & Services

Product quality testing; chemical research; bacteriological research; biological research; Medical and Scientific research, namely, conducting clinical trials for others; medical research; biological cloning services; stem cell research services; medical research laboratory services; genetic testing for scientific research purposes

Medical clinic services; telemedicine services; therapy services, namely, cognitive therapy services, voice and speech therapy services, insomnia therapy services, physiotherapy, psychological counseling services, psychotherapy services, respiratory therapy services, drug rehabilitation counseling services, addiction treatment services; stem cell therapy services; health counselling; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; convalescent home services; advisory services relating to health; services of a psychologist; massage; rental of sanitary installations

Medicines for human purposes, namely, medicines for the treatment of degenerative disease, motor neuron disease; medicines for human purposes, namely, medicines for the treatment of epilepsy; medicines for human purposes, namely, medicines for the treatment of macular degeneration; medicines for human purposes, namely, medicines for alleviating constipation; medicines for human purposes, namely, medicines for the treatment of cardiovascular disease, coronary heart disease, angina pectoris, myocarditis, cardiac arrhythmia, tumors, infectious diseases, autoimmune disease, blood disease, mental illness, ophthalmic disorders, metabolic diseases and disorders in the nature of diabetes, kidney diseases, osteoporosis; pharmaceutical preparations, namely, antivirals; pharmaceutical preparations, namely, anesthetics for surgical and non-surgical use; drugs for medical purposes, namely, antibiotics and bacterial poisons; medicines for human purposes, namely, biological preparations in the nature of serums, prepared by using biological materials in the nature of microorganisms, cells, and various animal and human tissues and liquids, obtained by biological techniques, namely, genetic engineering, cell engineering, protein engineering, fermentation engineering for the treatment of central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, antipyretic and analgesic purposes, non-steroidal anti-inflammatory purposes, infectious diseases, autoimmune diseases, anti-tumor purposes, hypoglycemic and diuretic purposes, vitamin and hormonal purposes; medicines for human purposes, namely, parenteral nutrition supplements; Transplants, namely, bone graft materials derived from human tissue, processed human donor skin for the replacement of soft tissue, surgical mesh comprised primarily of living tissue, specifically, ex vivo cells, namely, immune cells, red blood cells, t cells, nk cells, islet cells; collagen for medical purposes; immunostimulants; nutraceutical preparations for therapeutic or medical purposes for use in the treatment of degenerative diseases; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment and prevention of cancer; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for reducing cholesterol; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases and arthritis; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparation for treating microbial diseases, namely, antibiotics; pharmaceutical preparations for the treatment of mental illness and ophthalmic disease; pharmaceutical preparations for infectious disease, blood disease and kidney disease; pharmaceutical preparations containing chemical drugs and biological preparations in the nature of serums for the prevention and treatment of central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, infectious diseases, autoimmune diseases; pharmaceutical preparations containing chemical drugs and biological preparations in the nature of serums for antipyretic and analgesic purposes, non-steroidal anti-inflammatory purposes, anti-tumor purposes, hypoglycemic and diuretic purposes, vitamin and hormonal purposes and parenteral nutrition purposes; chemico-pharmaceutical preparations for the treatment of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases and infectious diseases; chemico-pharmaceutical preparations for relief from asthma and coughs; chemico-pharmaceutical preparations for parenteral nutrition purposes, antipyretic and analgesic purposes, non-steroidal anti-inflammatory purpose, anti-tumor purposes, hypoglycemic and diuretic purposes, vitamin and hormonal purposes; pharmaceutical preparations for use in tissue and organ transplantation, pharmaceutical preparations for human use for the prevention of solid organ transplant rejection, pharmaceutical preparations for transplantation and transplant-related conditions affecting the kidney; vaccines; drugs in the nature of pharmaceutical preparations for medical purposes for the treatment of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, infectious diseases, autoimmune disease; drugs in the nature of pharmaceutical preparations for medical purposes for relief from asthma and coughs; drugs in the nature of pharmaceutical preparations for medical purposes, namely, parenteral nutrition purposes, antipyretic and analgesic purposes, nonsteroidal antiinflammatory purpose, anti-tumor purposes, hypoglycemic and diuretic purposes, vitamin and hormonal purposes; serums for medical purposes for treatment of skin; opotherapy preparations; blood plasma; biological preparations for medical purposes, namely, antitoxic sera, antitoxins, toxoids, toxins, human and veterinary vaccines, and for use in cell cultures; medicines for veterinary purposes, namely, veterinary pharmaceutical preparations for respiratory and reproductive diseases in cattle, veterinary pharmaceutical preparations for the treatment of arthritis, muscle soreness and sprains, veterinary pharmaceutical preparations for the treatment of bacterial infections in dogs, veterinary pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections, topical infections; veterinary pharmaceutical preparations for the treatment of infectious diseases, namely, swine dysentery, bacterial enteritis, bluecomb, pneumonia; veterinary pharmaceutical preparations for the treatment of vitamin deficiencies; veterinary preparations for treatment of intestinal bacteria; enzymes for medical purposes; enzyme preparations for medical purposes; diagnostic biomarker reagents for medical purposes; medicines for veterinary purposes, namely, laxatives for veterinary purposes, pain relief medication for veterinary purposes, suppositories for veterinary purposes; stem cells for veterinary purposes; biological tissue cultures for veterinary purposes

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Feb 19, 2026 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 2, 2026 FICS
FINAL DISPOSITION PROCESSED
Feb 2, 2026 FIMP
CHANGE OF NAME/ADDRESS REC'D FROM IB
Oct 18, 2025 ADCH
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 8, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 8, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 8, 2025 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jul 5, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 17, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jun 17, 2025 OPNR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 20, 2025 NPUB
PUBLISHED FOR OPPOSITION
May 20, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 14, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 21, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 15, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 15, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Apr 15, 2025 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Nov 6, 2024 GNFN
FINAL REFUSAL E-MAILED
Nov 6, 2024 GNFR
FINAL REFUSAL WRITTEN
Nov 6, 2024 CNFR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 18, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 18, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 18, 2024 REAP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 17, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 17, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 17, 2024 REAP
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 13, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 13, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 13, 2024 TROA
REFUSAL PROCESSED BY IB
Aug 4, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 15, 2024 RFCS
REFUSAL PROCESSED BY MPU
Jul 15, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 22, 2024 RFCR
NON-FINAL ACTION WRITTEN
Jun 21, 2024 CNRT
ASSIGNED TO EXAMINER
Jun 13, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 23, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 19, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 18, 2024 REPR